更新于：2024-04-01

GLP-1R

胰高血糖素样肽-1受体

更新于：2024-04-01

基本信息

别名

胰高血糖素样肽-1受体、胰高血糖素类肽-1受体、GLP-1 receptor

+ [5]

简介

G-protein coupled receptor for glucagon-like peptide 1 (GLP-1) (PubMed:8405712, PubMed:8216285, PubMed:7517895, PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449). Ligand binding triggers activation of a signaling cascade that leads to the activation of adenylyl cyclase and increased intracellular cAMP levels (PubMed:8405712, PubMed:8216285, PubMed:7517895, PubMed:19861722, PubMed:26308095, PubMed:27196125, PubMed:28514449). Plays a role in regulating insulin secretion in response to GLP-1 (By similarity).

关联

337

利拉鲁肽生物类似药 (通化东宝)

靶点

GLP-1R

作用机制

GLP-1R激动剂

在研机构

通化东宝药业股份有限公司

原研机构

通化东宝药业股份有限公司

在研适应症

2型糖尿病

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2023-11-28

Liraglutide biosimilar (Zhongmei Huadong)

利拉鲁肽生物类似药 (中美华东)

靶点

GLP-1R

作用机制

GLP-1R激动剂

在研机构

杭州中美华东制药有限公司

原研机构

杭州中美华东制药有限公司

在研适应症

肥胖 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2023-03-28

Tirzepatide

替尔泊肽

靶点

GIPR x GLP-1R

作用机制

GIPR激动剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2022-05-13

2,765

项与 GLP-1R 相关的临床试验

NCT06222437 / Not yet recruiting临床1期IIT

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

开始日期2025-01-01

申办/合作机构

Methodist Health System, Inc.

NCT05714683 / Not yet recruitingN/A

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.

开始日期2024-12-31

申办/合作机构

Novo Nordisk A/S

NCT06073184 / Not yet recruiting临床2期

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.

开始日期2024-09-01

申办/合作机构

University Health Network

100 项与 GLP-1R 相关的临床结果

登录后查看更多信息

100 项与 GLP-1R 相关的转化医学

登录后查看更多信息

0 项与 GLP-1R 相关的专利（医药）

登录后查看更多信息

3,870

项与 GLP-1R 相关的文献（医药）

2024-12-01·Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

GLP1R boosts survival, migration and invasion of endometrial cancer cells and protects against ferroptotic cell death.

Article

作者: Wu Li ; Wen Lyu ; Songjun Liu ; Fan Ruan ; Xinmei Zhang

BACKGROUND:

Despite the strong evidence concerning carcinogenic roles of glucagon-like peptide 1 receptor (GLP1R), the role of this gene in endometrial cancer (EC) remains elusive. This study investigated the properties of GLP1R on EC in vitro.

METHODS:

The expression of GLP1R in EC was detected by RT-qPCR, immunohistochemistry, and western blotting. Cell viability, cell cycle, apoptosis, migration, invasion and ferroptosis were assessed through CCK-8, flow cytometry, wound healing, transwell, DCFH-DA and western blotting, respectively.

RESULTS:

We found that GLP1R was up-regulated in EC than normal specimens. It had the highest expression in AN3CA cells. Cell viability, migration and invasion were significantly reduced, while cell cycle arrest and apoptosis were induced following GLP1R knockdown. The malignant biological behaviours of AN3CA cells were investigated when treated with exendin-4 (GLP1R agonist). Moreover, GLP1R lowered intracellular ROS level and expression of SLC7A11, and FTH1, but mitigated GPX4 expression in AN3CA cells.

CONCLUSION:

In a word, GLP1R was up-regulated in EC and its up-regulation facilitated the proliferative and metastatic potentials, and protected cells from ferroptosis, thereby accelerating EC progression. These data emphasised the potency of GLP1R as a therapeutic agent against EC.

2024-03-01·American journal of preventive cardiology

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020.

Article

作者: Joshua A Jacobs ; Alexander R Zheutlin ; Catherine G Derington ; Jordan B King ; Ambarish Pandey ; Adam P Bress

Objective:

Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2Is) lower adverse cardiac and kidney events among high-risk patients with diabetes mellitus (DM) and are now guideline-recommended as first-line therapy alongside metformin. However, the adoption of these new treatments from 2015 to 2020 among the highest-risk adults with DM remains unclear.

Methods:

We performed a cross-sectional analysis of the National Health and Nutrition Examination Surveys (NHANES) 2015-2020 to estimate the use of GLP1-RAs and SGLT2Is among adults with DM overall and by level of cardiovascular and kidney risk (CKR). We defined high CKR by history of atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), heart failure, or age ≥55 years with at least 2 ASCVD risk factors (i.e., obesity, hypertension, hyperlipidemia, or current smoker).

Results:

Overall, 2,432 participants with DM (mean age 60.6 years, 46.8 % female, 58.8 % Non-Hispanic White) were included, of which 1,869 and 563 were with and without high CKR, respectively. Participants with vs. without high CKR were more likely to be older, have higher systolic blood pressure, lower estimated glomerular filtration rate, use oral antidiabetic agents, and have health insurance. Overall, the weighted prevalence of GLP1-RA or SGLT2I was 9.0 % (95 % confidence interval [CI] 6.9-11.0): 4.8 % (95 % CI 3.6-6.1) took GLP1-RAs, and 5.1 % (95 % CI 3.3-7.0) took SGLT2Is. Use of GLP1-RAs or SGLT2Is did not differ between participants with vs. without high CKR (adjusted prevalence ratio [aPR] 1.00; 95 % CI 0.98-1.02). Participants with ASCVD were more likely to be on a GLP1-RA or SGLT2I (aPR 1.28; 95 % CI 1.25-1.31), while adults with CKD were less likely (aPR 0.84; 95 % CI 0.82-0.86).

Conclusion:

Among US adults with DM, GLP1-RA and SGLT2I use was low regardless of CKR. Data since 2020 analyzing the utilization of GLP1-RAs and SGLT2Is among high-CKR patients with DM is needed to identify implementation strategies for increased utilization.

2024-02-23·European stroke journal

Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis.

Article

作者: Maria-Ioanna Stefanou ; Aikaterini Theodorou ; Konark Malhotra ; Diana Aguiar de Sousa ; Mira Katan ; Lina Palaiodimou ; Aristeidis H Katsanos ; Ioanna Koutroulou ; Vaia Lambadiari ; Robin Lemmens ; Sotirios Giannopoulos ; Andrei V Alexandrov ; Gerasimos Siasos ; Georgios Tsivgoulis

INTRODUCTION:

Mounting evidence suggests that glucagon-like-peptide-1 receptor-agonists (GLP-1 RAs) attenuate cardiovascular-risk in type-2 diabetes (T2DM). Tirzepatide is the first-in-class, dual glucose-dependent-insulinotropic-polypeptide GIP/GLP-1 RA approved for T2DM.

PATIENTS AND METHODS:

A systematic review and meta-analysis of randomized-controlled clinical trials (RCTs) was performed to estimate: (i) the incidence of major adverse cardiovascular events (MACE); and (ii) incidence of stroke, fatal, and nonfatal stroke in T2DM-patients treated with GLP-1 or GIP/GLP-1 RAs (vs placebo).

RESULTS:

Thirteen RCTs (9 and 4 on GLP-1 RAs and tirzepatide, respectively) comprising 65,878 T2DM patients were included. Compared to placebo, GLP-1RAs or GIP/GLP-1 RAs reduced MACE (OR: 0.87; 95% CI: 0.81-0.94; p < 0.01; I² = 37%), all-cause mortality (OR: 0.88; 95% CI: 0.82-0.96; p < 0.01; I² = 21%) and cardiovascular-mortality (OR: 0.88; 95% CI: 0.80-0.96; p < 0.01; I² = 14%), without differences between GLP-1 versus GIP/GLP-1 RAs. Additionally, GLP-1 RAs reduced the odds of stroke (OR: 0.84; 95% CI: 0.76-0.93; p < 0.01; I² = 0%) and nonfatal stroke (OR: 0.85; 95% CI: 0.76-0.94; p < 0.01; I² = 0%), whereas no association between fatal stroke and GLP-1RAs was uncovered (OR: 0.80; 95% CI: 0.61-1.05; p = 0.105; I² = 0%). In secondary analyses, GLP-1 RAs prevented ischemic stroke (OR: 0.74; 95% CI: 0.61-0.91; p < 0.01; I² = 0%) and MACE-recurrence, but not hemorrhagic stroke (OR: 0.92; 95% CI: 0.51-1.66; p = 0.792; I² = 0%). There was no association between GLP-1RAs or GIP/GLP-1 RAs and fatal or nonfatal myocardial infarction.

DISCUSSION AND CONCLUSION:

GLP-1 and GIP/GLP-1 RAs reduce cardiovascular-risk and mortality in T2DM. While there is solid evidence that GLP-1 RAs significantly attenuate the risk of ischemic stroke in T2DM, dedicated RCTs are needed to evaluate the efficacy of novel GIP/GLP-1 RAs for primary and secondary stroke prevention.

1,870

项与 GLP-1R 相关的新闻（医药）

2024-03-31

·药融圈

5月广州千人大会 | XDC/小分子/GLP-1及多肽/高潜力企业展示

第八届NDC2024将于2024年5月30-31日在广州举办。本届大会话题内容将以“新成果、新趋势、新未来”为主旋律，涵盖小分子药物研发、XDC药物研发、GLP-1及多肽、核素药物开发等行业热门领域，同时设置高潜力企业展示论坛，届时，80+重磅大咖将汇聚广州，诚挚邀请您莅临参会，共同助推医药研发行业持续创新发展，挖掘未被满足的临床需求。#小分子 #PROTAC#多肽偶联药物、#多肽减重药物、#XDC#核药#CMC#立项策略#未来趋势#AI与CADD助力新药开发及其他新技术*报名通道限时免费现在就报名抢占席位更新中，以会议现场为准...近十年全球及国内小分子药物开发趋势从创投基金视角，浅谈新药科技成果转化眼科药物开发实例不可成药靶点&AI&&PROTAC&新技术小分子创新药研发布局与商业化小分子CMC抗病毒创新药物研发实例小分子创新药物的质量研究新型药物筛选研发平台药物发现-从“经验设计”到“合理设计”优秀小分子企业研发实例小分子改良药物开发首批意向出席嘉宾*嘉宾排名不分先后，按姓氏首字母A-Z排序陈小新众生睿创，联合创始人&总裁&董事陈元伟海创药业，董事长&创始人程浩富汇创投，合伙人杜新埃格林医药，联合创始人&CEO段建新艾欣达伟，董事长&总经理冯胜昔艾奇西，创始人冯焱领泰生物，创始人&CEO葛建润佳医药，研发副总裁胡永韩信诺维，联合创始人&董事&CTO华烨烨辉医药，创始人&CEO黄慧瑜美济生物，首席科学官姜非康哲药业，大中华区首席投资官李英富成都海博为，创始人&董事长欧阳晖因明生物，CTO欧阳亮四川大学，教授王永辉辉启生物，创始人&首席科学家魏用刚百裕药业，创新药研发总经理夏明德英诺湖，CEO张晓东赛诺哈勃，副总裁朱凌峰药融云，副总经理ADC药物早期生物学评价ADC作为靶向递送新方案的挑战和优势ADC药物靶点的筛选及适应症的确认要素从靶点发现到IND申报面临的挑战和解决方案对标全球市场，ADC药物的研发现状及差异化研发ADC药物开发关键：元件筛选及组合考量基于定点偶联技术的ADC药物开发成药性最佳的Linker-payload开发确证临床有效性和安全性的ADC药物设计要点ADC药物在非肿瘤领域的临床研究进展ADC药物临床开发挑战及药效学审评要点ADC药物临床前研究（药效，药代，安全性）ADC药物分析及质控ADC药物工艺开发及生产出海与国际化PDC新药CMC关键点XDC新型药物连接子（Linker）的合成与工艺开发XDC药物开发从发现到成药性/CMC的挑战与考量要素优秀企业ADC药物开发项目及成果展示首批意向出席嘉宾*嘉宾排名不分先后，按姓氏首字母A-Z排序蔡学钧前 BMS，全球研发副总裁李黎爱思益普生物，副总裁缪仕伟尚健生物，联合创始人&董事&高级副总裁刘大涛迈威生物，CEO秦刚启德医药，CEO盛严慈复宏汉霖，生物制药全球战略与项目管理总经理唐华东植德律所，合伙人王春河达石药业，董事长 &创始人袁韫聪华西海圻，项目总监朱义百利药业，创始人&董事长GLP-1药物市场竞争格局下一代口服GLP-1R激动剂开发GLP-1的偶联开发策略GLP-1的长效开发策略GLP-1药物药效学评价GLP-1药物安全性评价GLP-1药物的CMC开发策略GLP-1药物的注册申报GLP-1临床试验设计案例分享多肽类分子库高通量实体筛选体系及其特色应用开发抗感染多肽新药从头设计与临床开发基于连续化学工艺的液相多肽合成固相多肽合成方法的技术创新合成多肽药物工艺优化多肽表征分析策略化学合成多肽的分离纯化方法多肽药物的质量研究多肽药物制剂工艺研究多肽药物GMP生产的规范经验分享基于QBD的多肽药物质量控制多肽原料药质量控制和分析方法多肽药物绿色合成工艺多肽药物CMC一体化开发策略多肽药物杂质研究首批意向出席嘉宾*嘉宾排名不分先后，按姓氏首字母A-Z排序陈伟甘李药业，副总经理刘东舟华东医药，CSO&创新药全球研发中心总经理郭海兵瀚辰星泰，创始人&CEO林熹晨硕迪生物，首席科学官兼总裁刘日勇派金生物，联合创始人&常务副总韦沂均成都惠泰生物，CEO温晓芳道尔生物，副总裁颜杰信立泰，研究院院长左亚军仁会生物，总经理靶向Nectin4核素偶联药物的开发高通量筛选技术与放射性新药物发现与优化靶向GPC3放射性药物的筛选与开发靶向放射性核素疗法的迭代与升级的展望放射性药物CMC的全面解析核药临床前研究放射性药物的临床试验设计策略与实践：放射性药物注册之路从投资角度看待放射性药物赛道临床经验分享：靶向放射性药物对多发转移肿瘤治疗的优势传统核药企业的创新管线布局首批意向出席嘉宾*嘉宾排名不分先后，按姓氏首字母A-Z排序杜方勇通瑞药业，CTO邓启民云克药业，副总经理单波苏州博锐创合，CEO洪浩四体康宸，联合创始人&CTO习宁医诺维申，创始人&董事长&CEO高潜力医药企业项目展示抗肿瘤药物开发实例肺癌药物开发实例罕见病药物开发实例精神障碍类药物开发实例CNS药物开发实例心血管疾病药物开发实例血液系统疾病药物开发实例生殖系统疾病药物开发实例呼吸系统疾病新药开发实例神经退行性疾病药物开发实例生殖系统疾病药物开发实例儿童药开发实例免疫系统疾病药物开发实例抗病毒类药物开发实例首批意向出席嘉宾*嘉宾排名不分先后，按姓氏首字母A-Z排序陈柏州加立生科，CEO韩照中领诺医药，创始人&CEO张在军喜鹊医药，副总经理朱永强江苏正大丰海制药，副总经理/药物研究院院长*报名通道限时免费现在就报名抢占席位*嘉宾排名不分先后，按姓氏首字母A-Z排序赞助/参展/演讲火热招募中！主题演讲、展位产品展示、广告赞助、独家会议袋/吊绳/吊牌等多种合作形式开放，为您提供全方位品牌宣传及合作交流平台，诚邀您的参与！商务合作福利、收费标准等详情请咨询：张女士 15005862516王女士 18858579027刘女士 13777548559李先生 13340291890政府合作咨询：袁女士 13883559741*报名通道限时免费参会咨询：林女士 18857750934• 大湾区新药峰会：瞄准创新药项目，高潜力企业已就位！• 第二届大湾区(广州)生物医药创新者峰会日程• 第三届上海新药创新者峰会快速查• 第五届大湾区（广州）生物医药创新者峰会日程• 第七届成都生物医药创新者峰会往届参会企业列表（部分）*上下滑动查看更多

抗体药物偶联物蛋白降解靶向嵌合体多肽偶联药物

2024-03-29

·梅斯医学

科学减肥策略集锦：每周一次可减重40斤；阻力训练或可改善肥胖、代谢风险和炎症……

肥胖是一种广泛存在的慢性、复发性和进行性疾病，对个人和社会具有重大不良影响。各种健康并发症（包括2型糖尿病、高血压和心血管疾病等）与超重和肥胖相关，这些并发症的患病率随着体重指数（BMI）的增加而增加。世界卫生组织（WHO）将肥胖定义为BMI≥30 kg/m2。而中国肥胖工作组将超重定义为BMI≥24.0 kg/m2，将肥胖定义为28.0 kg/m2。根据中国肥胖工作组的定义，2015年~2019年中国成人超重和肥胖患病率分别估计为34.3%和16.4%，预计到2030年，超重和肥胖的综合患病率将攀升至65%。每周一次可平均减重12.1%！司美格鲁肽也适用于这类人群！除了生活方式干预和减肥手术外，药物治疗在慢性体重管理中也起着重要作用。在STEP（司美格鲁肽用于肥胖患者的治疗效果）临床试验项目中，司美格鲁肽2.4 mg每周一次皮下注射可显著并持续降低超重或肥胖成人的体重。既往STEP 6试验还在东亚人群中评估了该疗法的疗效，显示其相比安慰剂可以显著减轻体重且具有临床意义。STEP 7试验于近期发表于The Lancet Diabetes & Endocrinology，旨在进一步评估司美格鲁肽2.4 mg每周一次在东亚成人体重管理中的有效性和安全性。研究结果显示，在伴或不伴有2型糖尿病的超重或肥胖东亚人群中，司美格鲁肽2.4 mg每周一次皮下注射与安慰剂相比，可显著减轻体重且具有临床意义。从基线至第44周，与安慰剂组相比，司美格鲁肽组的平均体重减少更多：司美格鲁肽2.4 mg组体重的估计平均百分比变化为-12.1%，而安慰剂组为-3.6%（估计治疗差异-8.5%[95% CI -10.2%~-6.8%]；P<0.0001）。在第44周，司美格鲁肽2.4 mg组体重减轻5%或更多的受试者比例高于安慰剂组（203/238[85%] vs. 36/116[31%]）；比值比[OR] 13.1（95% CI 7.4~23.1；P<0.0001）。每周一次可减重达40斤！双重激动剂用于肥胖人群获益显著目前，研究肥胖治疗的其他靶点以改善治疗结局仍然是当务之急。Survodutide是一种胰高血糖素受体/胰高血糖素样肽-1受体（GCGR/GLP-1R）双重激动剂，可每周给药一次。该疗法的临床前研究分析表明，在小鼠模型中，通过同时作用于GCGR和GLP-1R，其治疗可比现有获批的胰高血糖素样肽-1（GLP-1）类药物更大程度地减轻体重。近期，The Lancet Diabetes & Endocrinology发表了关于survodutide治疗肥胖的2期试验结果，研究分析显示，在BMI≥27 kg/m2的非糖尿病成人中，与安慰剂组相比，所有测试剂量的survodutide均能显著减轻受试者的体重（其中0.6 mg组P值为0.026；≥2.4 mg组P值均小于0.0001）。具体而言，按照survodutide治疗计划方案，survodutide 0.6 mg、2.4 mg、3.6 mg、4.8 mg组受试者体重从基线至第46周分别降低6.2%、12.5%、13.2%和14.9%，而安慰剂组降低了2.8%。不过实际治疗期间，接受survodutide 0.6 mg、2.4 mg、3.6 mg、4.8 mg治疗的受试者体重可分别降低6.8%、13.6%、16.7%和18.7%，相当于绝对体重分别减少7.2 kg、13.8 kg、17.1 kg和19.5 kg。图片来源：123RF每周一次总平均减重25.3%！Tirzepatide持续治疗，可保持至少80%的体重减轻Tirzepatide是一种葡萄糖依赖性促胰岛素多肽（GIP）和GLP-1双重受体激动剂，已在包括美国、欧盟和日本在内的许多国家获得批准为每周一次的皮下注射剂以用于治疗2型糖尿病，并在美国和英国获批用于治疗肥胖。在一项针对超重或肥胖但无糖尿病的受试者的安慰剂对照试验中，采用tirzepatide治疗72周后，受试者平均体重减少20.9%。发表于JAMA的一项研究，旨在评估持续使用每周一次、最大耐受剂量（10 mg或15 mg）的tirzepatide配合饮食和身体活动对维持体重减轻的效果。这项研究包括36周的开放标签tirzepatide导入期以及随后的52周双盲安慰剂对照期。研究结果显示，从第36周至第88周，tirzepatide组平均体重变化百分比为-5.5%，安慰剂组为14.0%（差异为-19.4%[95% CI，-21.2%~-17.7%]；P<0.001）。有300例（89.5%）受试者在88周时接受tirzepatide治疗，并在导入期保持了至少80%的体重减轻，而接受安慰剂治疗的受试者为16.6%（P<0.001）。从第0周至第88周，tirzepatide组的总体平均体重减轻25.3%，安慰剂组为9.9%。在超重或肥胖人群中，这两种运动策略均可改善心血管风险心血管疾病（CVD）是导致死亡的主要原因。身体活动（特别是有氧运动）已被证实可以预防CVD。然而，很少有临床试验在超重或肥胖人群中直接评估抗阻训练、抗阻训练联合有氧运动与单独有氧运动相比是否能提供相似或更强的心血管益处。发表于European Heart Journal的一项研究对比进行了评估。研究分析显示，在超重或肥胖成人中，与对照组相比，单独有氧运动或抗阻训练联合有氧运动可改善复合CVD风险（即包括收缩压、低密度脂蛋白胆固醇、空腹血糖和体脂百分比在内的4种已确定的CVD危险因素的标准化复合风险，用z评分表示）。在超重或肥胖成人中，与对照组相比，单独有氧运动（平均差，-0.15[95% CI：-0.27~-0.04]；P=0.01）、阻力训练联合有氧运动（平均差，-0.16[95% CI：-0.27~-0.04]；P=0.009]）的综合z评分在1年时下降，这表明CVD风险状况有所改善，但在单独抗阻训练中则没有。与单独抗阻训练相比，单独有氧运动、阻力训练联合有氧运动的综合z评分降低幅度更大（P均=0.03），单独有氧运动、抗阻训练联合有氧运动之间没有差异（P=0.96）。在这类超重/肥胖人群中，阻力训练或可改善身体肥胖、代谢风险和炎症绝经后的特点是卵巢功能丧失（即雌激素水平低），这与身体脂肪水平增加（特别是腹部脂肪）以及炎症和代谢功能受损有关。公共卫生指南建议将阻力训练作为一种非药物干预措施，以改善身体健康（如心肺健康、肌肉健康和身体成分等），并限制慢性疾病和其他致残状况的发生及发展。发表于Journal of Sport and Health Science的一项研究，旨在评估阻力训练量对绝经后老年女性身体肥胖、代谢风险和炎症的影响。研究结果显示，与对照组相比，两个阻力训练组（包括低负荷阻力训练[LVRT]，~44组/周；和高负荷阻力训练[HVRT]，~77组/周）的身体肥胖、代谢风险和炎症均有所改善；不过，在超重/肥胖绝经后老年女性中，HVRT比LVRT更能改善代谢风险和炎症结局。但需要注意的是，每个人应根据自己的情况来进行合适的运动量。参考资料（可上下滑动查看）[1] Mu Y, et al., (2024). Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol, doi: 10.1016/S2213-8587(23)00388-1.[2] le Roux CW, et al., (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol, doi: 10.1016/S2213-8587(23)00356-X.[3] Aronne LJ, et al., (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, doi: 10.1001/jama.2023.24945.[4] Lee DC, et al., (2024). Aerobic, resistance, or combined exercise training and cardiovascular risk profile in overweight or obese adults: the CardioRACE trial. Eur Heart J, doi: 10.1093/eurheartj/ehad827.[5] Nunes PRP, et al., (2024). Effect of resistance training volume on body adiposity, metabolic risk, and inflammation in postmenopausal and older females: Systematic review and meta-analysis of randomized controlled trials. J Sport Health Sci, doi: 10.1016/j.jshs.2023.09.012.撰文 | 医学新视点编辑 | Swagpp● 震惊！大三甲医生惨痛教训：35岁住院医，工作6年，跟风读研后反而找不到工作了！网友：为读研而读研你太傻！学历贬值你不懂?● 柳叶刀最新：全球生育率持续下降，逼近临界值！25年后，近50%国家的自然增长率为负，中国人口将持续减少● 重磅！！国家卫健委：2024年将推进“先诊疗后付费”等新模式！依靠信用，“花呗”版看病真的来了！意味着什么？版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果

2024-03-28

·BioSpace

Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH

Pictured: 3d illustration of hepatitis B viruses/iStock/Artur Plawgo Maryland-based Altimmune is eliminating its hepatitis B program after the company’s HepTcell candidate failed a Phase II trial, the biotech revealed Wednesday. According to Altimmune, results from the Phase II trial investigating the efficacy of HepTcell showed it to be “insufficient to warrant further advancement” and that further development has been halted. The candidate is an immunotherapeutic designed to drive CD4+ and CD8+ T-cell responses against all hepatitis B virus genotypes in patients. Phase I results, according to Altimmune, did manage to reach the primary endpoint of safety. With Altimmune’s pullback from hepatitis B, the focus is now on the red-hot obesity market as the biotech’s candidate, pemvidutide, is showing encouraging data. In Phase II results for the injectable drug, released in November 2023, the company reported mean weight loss of 15% based on a 2.4-mg dose at week 48. At the highest pemvidutide dose level, more than 30% of patients lost at least 20% of their weight. Pemvidutide is an investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). On Thursday, Altimmune touted the recently completed MOMENTUM 48-week Phase II obesity trial for pemvidutide. “Our data show that 74.5% of weight loss was derived from adipose tissue and only 25.5% from lean mass, comparable to the effects historically associated with weight loss from diet and exercise programs,” Altimmune CEO Vipin Garg said in a statement. The “compelling” weight loss data shows that pemvidutide can “distinguish itself” from other therapies in the obesity space, according to Garg, who added that the company is anticipating results from its Phase IIb MASH trial sometime in the first quarter of 2025. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

临床2期临床结果